Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05579977 · ClinicalTrials.gov registry record · Phase 2
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 902
- Enrollment target
NCT05579977: Clinical Trial Phase 2 study, sponsored by Pfizer.
NCT05579977 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 902 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (578% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05579977, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 902 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Rybelsus. Those in the obesity part of the study, will receive either active study drug or placebo. The study will last for about 36 weeks except for the first 25% of the participants that enter in which case the study will last for approximately 48 weeks. during this time there will be visits every 4 weeks with phone calls in between.
Interventions
- OTHER Placebo
- DRUG PF-07081532
- DRUG Rybelsus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 902 participants |
| Start Date | 2022-10-27 |
| Est. Completion | 2023-09-22 |
| Phase | Phase 2 |
Why NCT05579977 stopped before completion
NCT05579977 is an interventional study that assigns participants to a tested intervention. The registered 902 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (578% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05579977 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05579977 about?
NCT05579977 is a clinical study titled "Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity". The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals...
What is the current status of trial NCT05579977?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 902 participants. The study started on 2022-10-27. Estimated completion is 2023-09-22.
What interventions are being tested in trial NCT05579977?
The interventions under investigation include: Placebo (OTHER), PF-07081532 (DRUG), Rybelsus (DRUG).
Who is sponsoring clinical trial NCT05579977?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05579977's enrollment target sits among peer trials
902 30th of 2000 higher than 1,971 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI